Atlas Trials

EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)

Clinical trial NCT07646171 · RECRUITING

Trial details

NCT number
NCT07646171
Sponsor
Tel-Aviv Sourasky Medical Center
Status
RECRUITING
Study type
OBSERVATIONAL
Hormone Receptor Positive Breast Cancer
Start date
2022-09-01
Primary completion
2026-12-31
Enrollment
19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.